Fabien Pictet

Astralis Ltd. research and develop drugs for the treatment of immune system disorders and skin diseases. The company's initial product is Psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The company's second product is for the treatment of leishmaniasis. The company was founded on June 30, 2001 and is headquartered in Fairfield, NJ.

The Ukraine Opportunity Trust Ltd. operated as a closed-end investment fund/investment trust. Its investment objective is to achieve long-term capital growth primarily from a diversified portfolio of companies incorporated, headquartered or domiciled in, or whose businesses are primarily carried on in, Ukraine. The company was founded on August 16, 2005 and was headquartered in London, the United Kingdom.

Banque Pictet & Cie SA is an independent Swiss private bank which specializes in asset and wealth management. Headquartered in Geneva, the firm was founded in 1805 to manage the wealth of private and institutional investors. They do not engage in investment banking and do not issue commercial, mortgage or unsecured loans.

FPP Asset Management LLP (FFP) is the Great Britain-based specialist fund management subsidiary of Fabien Pictet & Partners Ltd., itself a subsidiary of Fabien Pictet & Partners Global Holdings Ltd. In Cayman Islands. The firm was founded by Fabien Pictet, Jonathan Neill and Julian Jacobson in 1998. Headquartered in London, FFP manages assets on behalf of a sophisticated and diverse client base that includes pension funds, family offices, private banks and ultra-high net worth individuals.